ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

NCT00141453 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

577

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Nephropathy
Type 2 Diabetes Mellitus
Proteinuria

Interventions

DRUG: olmesartan medoxomil
DRUG: Placebo Tablets

Sponsor

Daiichi Sankyo Co., Ltd.